Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways

Regardless of the presence or absence of specific diagnostic mutations, many cancer patients fail to respond to EGFR-targeted therapeutics, and a personalized approach is needed to identify putative (non)responders. We found previously that human peripheral blood and EGF can modulate the activities...

Full description

Bibliographic Details
Main Authors: Dmitri Kamashev, Nina Shaban, Timofey Lebedev, Vladimir Prassolov, Maria Suntsova, Mikhail Raevskiy, Nurshat Gaifullin, Marina Sekacheva, Andrew Garazha, Elena Poddubskaya, Maksim Sorokin, Anton Buzdin
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cells
Subjects:
EGFR
HER-targeted cancer therapy
human blood serum
cetuximab
erlotinib
EGF
Online Access:https://www.mdpi.com/2073-4409/12/16/2022

Similar Items

Similar Items